Johnson & Johnson announced this morning data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.

In anticipation of the potential need for boosters, the company conducted two Phase 1/2a studies in individuals previously vaccinated with its single-shot vaccine.

New interim data from these studies demonstrate that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination, Johnson & Johnson says.

Significant increases in binding antibody responses were observed in participants between ages 18 and 55, and in those 65 years and older who received a lower booster dose.